A New Class of Medicines through DNA Editing

Clinical Genome Editing Therapeutic editing of the human genome has long been a holy grail of genetic medicine. Different approaches are founded on a bedrock of basic laboratory discovery. This art...

[1]  Luigi Naldini,et al.  Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1 , 2017, Science Translational Medicine.

[2]  A. Waldman,et al.  Capture of DNA sequences at double-strand breaks in mammalian chromosomes. , 2001, Genetics.

[3]  Sruthi Mantri,et al.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells , 2016, Nature.

[4]  Richard L. Frock,et al.  Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR–Cas9 genome editing , 2017, Nature Biomedical Engineering.

[5]  Sruthi Mantri,et al.  Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans , 2018 .

[6]  Matthew C. Canver,et al.  BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis , 2015, Nature.

[7]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[8]  P. Rouet,et al.  Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Porteus,et al.  Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  R. Kucherlapati,et al.  Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination , 1985, Nature.

[11]  R. Dolmetsch,et al.  p 53 inhibits CRISPR – Cas 9 engineering in human pluripotent stem cells , 2018 .

[12]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[13]  David J. Rawlings,et al.  Tracking genome engineering outcome at individual DNA breakpoints , 2011, Nature Methods.

[14]  Richard L. Frock,et al.  Ectopic expression of RAD 52 and dn 53 BP 1 improves homology-directed repair during CRISPR – Cas 9 genome editing , 2017 .

[15]  M. Bétermier,et al.  Is Non-Homologous End-Joining Really an Inherently Error-Prone Process? , 2014, PLoS genetics.

[16]  J. Hoeijmakers,et al.  Molecular mechanisms of DNA double strand break repair. , 1998, Trends in cell biology.

[17]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[18]  J. Corn,et al.  CRISPR-Cas9 genome editing in human cells works via the Fanconi Anemia pathway , 2017, bioRxiv.

[19]  E. Haddad,et al.  Targeted gene addition to human mesenchymal stromal cells as a cell-based plasma-soluble protein delivery platform. , 2010, Cytotherapy.

[20]  R. Barrangou,et al.  CRISPR/Cas, the Immune System of Bacteria and Archaea , 2010, Science.

[21]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[22]  S. West,et al.  Double-strand break repair in human cells. , 2000, Cold Spring Harbor symposia on quantitative biology.

[23]  A. Scharenberg,et al.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template , 2015, Science Translational Medicine.

[24]  Alessandro Romanel,et al.  A highly specific SpCas9 variant is identified by in vivo screening in yeast , 2018, Nature Biotechnology.

[25]  D. Durocher,et al.  Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency , 2017, Nature Biotechnology.

[26]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[27]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[28]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[29]  M. Porteus,et al.  Human SMC 5 / 6 complex promotes sister chromatid homologous recombination by recruiting the SMC 1 / 3 cohesin complex to double-strand breaks , 2006 .

[30]  B. Dujon,et al.  Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae , 1995, Molecular and cellular biology.

[31]  Dana Carroll,et al.  Enhancing Gene Targeting with Designed Zinc Finger Nucleases , 2003, Science.

[32]  J. Joung,et al.  Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases , 2016, Nature Reviews Genetics.

[33]  Israel Steinfeld,et al.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells , 2015, Nature Biotechnology.

[34]  M. Porteus,et al.  Genome Editing: A New Approach to Human Therapeutics. , 2016, Annual review of pharmacology and toxicology.

[35]  M. Porteus,et al.  Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double‐strand breaks , 2006, The EMBO journal.

[36]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[37]  D. Russell,et al.  Human gene targeting by viral vectors , 1998, Nature Genetics.

[38]  P. Rouet,et al.  Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. , 1994, Molecular and cellular biology.

[39]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[40]  Dana Carroll,et al.  Genome engineering with targetable nucleases. , 2014, Annual review of biochemistry.

[41]  David Baltimore,et al.  Chimeric Nucleases Stimulate Gene Targeting in Human Cells , 2003, Science.

[42]  Margherita Neri,et al.  Site-specific integration and tailoring of cassette design for sustainable gene transfer , 2011, Nature Methods.

[43]  Philippe Horvath,et al.  A decade of discovery: CRISPR functions and applications , 2017, Nature Microbiology.

[44]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[45]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[46]  Andreas Reinisch,et al.  Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6 , 2017, eLife.

[47]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[48]  Gang Bao,et al.  Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. , 2014, Cell reports.

[49]  Tetsushi Sakuma,et al.  Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9 , 2014, Nature Communications.

[50]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[51]  Gang Bao,et al.  A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells , 2018, Nature Medicine.

[52]  Aymeric Duclert,et al.  Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. , 2015, Cancer research.

[53]  John A Zaia,et al.  Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells , 2016, Molecular therapy. Methods & clinical development.

[54]  Dana Carroll,et al.  Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. , 2002, Genetics.

[55]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[56]  H. Volk,et al.  High prevalence of S. pyogenes Cas9-specific T cell sensitization within the adult human population – A balanced effector/regulatory T cell response , 2018, bioRxiv.

[57]  Gregory McAllister,et al.  p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells , 2018, Nature Medicine.

[58]  Dana Carroll,et al.  Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells , 2016, Science Translational Medicine.

[59]  Ashley Williams,et al.  Genome Editing and Human Reproduction: Social and Ethical Issues , 2018 .

[60]  R. Bak,et al.  CRISPR/Cas9 genome editing in human hematopoietic stem cells , 2018, Nature Protocols.

[61]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[62]  Adrian J. Thrasher,et al.  Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells , 2017, Science Translational Medicine.

[63]  M. Porteus,et al.  Genome Editing of Mouse Fibroblasts by Homologous Recombination for Sustained Secretion of PDGF-B and Augmentation of Wound Healing , 2014, Plastic and reconstructive surgery.

[64]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[65]  Shondra M Pruett-Miller,et al.  High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases , 2011, Nature Methods.

[66]  Changyu Wang,et al.  TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy. , 2015, The Journal of clinical investigation.

[67]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[68]  David Cyranoski,et al.  CRISPR gene-editing tested in a person for the first time , 2016, Nature.

[69]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[70]  Srinivasan Chandrasegaran,et al.  Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells , 2005, Nucleic acids research.

[71]  Israel Steinfeld,et al.  Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  P. Glazer,et al.  Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing , 2018, Molecules.

[73]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[74]  H. Ochs,et al.  Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome. , 2016, Blood.

[75]  Dana Carroll,et al.  Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.